Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease

NCT05405114 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05405114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05405114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre Trial Evaluating the Efficacy and Safety of Oral Decitabine Tetrahydrouridine (NDec) in Patients With Sickle Cell Disease
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
July 7, 2022
Completion date
July 24, 2025
Enrollment
96 (actual)
Sites
118

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease